Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Recruiting

Phase 2

Gemcitabine & CisplatinGemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Sponsor:

Alliance for Clinical Trials in Oncology

Code:

NCT03609216

Conditions

Infiltrating Bladder Urothelial Carcinoma

Stage II Bladder Urothelial Carcinoma

Stage III Bladder Urothelial Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Gemcitabine Hydrochloride

Cisplatin

Pegfilgrastim

Conventional Surgery

Radical Cystectomy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-16. This information was provided to ClinicalTrials.gov by Alliance for Clinical Trials in Oncology on 2025-04-02.